Humoral immune responses following inactivated COVID-19 vaccine with different booster intervals: a randomized interventional immunogenicity study.

Authors

Xinyu Liu, Qianhui Hua, Rongrong Dai, Lanxin Ma, Ruijing Bao, Huijun Lei, Pengfei Yu, Yuting Liao, Juan Yang, Huakun Lv, Jianmin Jiang, Hangjie Zhang

Published in

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases. Pages 109196. Oct 19, 2026. Epub Oct 19, 2026.

Abstract

To evaluate the immunogenicity of booster doses at varying intervals after a two-dose primary series of inactivated COVID-19 vaccine.
This randomized, open-label interventional study in Zhejiang, China, allocated 431 participants via stratified block randomization to a control group (primary series only) or booster groups at 1, 4, 6, or 11 months after the primary series. Laboratory staff and statisticians were blinded. Immunogenicity endpoints included anti-RBD IgG, live-virus microneutralization, and pseudovirus neutralization against wild-type, Delta, and Omicron BA.1.
At 1 month post-booster, live wild-type neutralizing antibody GMT (Geometric mean titer) increased with longer intervals, from 42.96 (1-Month group) to 149.93 (11-Month group). Anti-RBD and anti-S1+N IgG concentrations were significantly higher in the 4-, 6-, and 11-Month group. Pseudovirus neutralization inhibition percentages decreased progressively across variants: wild-type (72.81%-86.70%), Delta (24.32%-35.82%), Omicron BA.1 (0.26%-2.97%). GMT declined substantially by 6 months post-booster (12.08 and 17.95 in the 1- and 4-Month group), and age was significantly negatively associated with humoral responses only in the 6-Month group.
All booster regimens elicited greater binding and neutralizing responses than the two-dose primary series, with peak responses at 1 month post-booster increasing progressively as the interval lengthened (up to 11 months). However, neutralizing activity against Omicron BA.1 was negligible across regimens, and antibody levels declined substantially by 6 months post-booster.

PMID:
42896726
Bibliographic data and abstract were imported from PubMed on 20 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.